Trump Administration Postpones Medicare Coverage Pilot for Weight-Loss Drugs Amid Insurer Hesitation

Trump Administration Postpones Medicare Coverage Pilot for Weight-Loss Drugs Amid Insurer Hesitation

The Trump administration has shelved a pilot initiative that would have expanded Medicare coverage for GLP-1 weight-loss medications following reluctance from major health insurers to participate in the program.

The proposed BALANCE pilot program aimed to allow Medicare-participating insurance providers to subsidize medications such as Wegovy and Zepbound as standard benefits, which would have limited patient copayments to just $50—substantially lower than the hundreds of dollars individuals currently pay out of pocket. However, the initiative has been delayed as health insurance companies expressed significant reservations about the program's structure.

Program Details and Current Status

Medicare, which serves more than 55 million Americans aged 65 and older, was the target population for this coverage expansion. The Trump administration had previously negotiated agreements with pharmaceutical manufacturers Eli Lilly and Novo Nordisk to reduce drug prices in exchange for access to additional patient populations.

While the pilot program has been postponed, existing Medicare beneficiaries already using these medications will continue to receive coverage through an alternative transitional program launching in July and extending through the end of 2027. Under this arrangement, Medicare itself will cover the costs rather than individual insurance carriers, according to reports.

Industry Concerns Drive Delay

Insurance companies operating within the Medicare system cited structural and financial concerns about the original proposal. Bobby Hunter, the head of UnitedHealth's Medicaid division—representing the nation's largest Medicare Advantage provider—stated during the company's earnings presentation this week:

"There are some notable challenges and outstanding questions with the currently planned structure."

The Centers for Medicare & Medicaid Services will use this postponement period to reassess the program's framework and develop more viable implementation strategies moving forward.

Medication Costs and Market Access

Without insurance coverage, GLP-1 injectable medications exceed $1,000 monthly for many patients. However, manufacturer discount programs have made these drugs more accessible. Current pricing through assistance programs includes:

• Novo Nordisk's Wegovy: approximately $349 per month
• Eli Lilly's Ozempic: approximately $349 monthly for doses up to 1 mg, with 2 mg doses at $499
• Eli Lilly's Zepbound: ranging from $499 to $1,086 monthly depending on dosage, though some lower-dose formulations are available at $299 per month

Therapeutic Benefits and Considerations

These medications offer significant clinical advantages for patients with diabetes and obesity, including improved blood sugar control, weight reduction, enhanced liver function, and decreased cardiovascular risk. Recent surveys indicate approximately one in eight American adults has utilized GLP-1 medications for weight management or chronic disease treatment.

The medications are not without drawbacks, however. Reported side effects include severe nausea, vision complications, gastrointestinal disturbances, and other adverse reactions affecting some users.